Ulcerative lymphomatoid papulosis following immune checkpoint inhibition and autologous stem cell transplant in a patient with recurrent Hodgkin lymphoma: a case report

Figures & data

Table 1. Cutaneous immune-related adverse events (irAEs) secondary to immune checkpoint inhibitors (ICIs) and differential diagnoses [13].

Cutaneous immune-related adverse events secondary to immune checkpoint inhibitors
Cutaneous irAEs secondary to ICIs	Differential diagnoses
Acantholytic dermatitis	Pemphigus Hailey-Hailey disease Darier disease Acantholytic acanthoma
Acneiform/follicular dermatitis or rosacea	Acne vulgaris Seborrheic dermatitis Suppurative folliculitis
Acute generalized exanthematous pustulosis	Pustular psoriasis Impetigo Candida infection Subcorneal pustular dermatosis
Bullous pemphigoid	Bullous arthropod reaction Allergic contact dermatitis Drug reaction Pemphigus vulgaris
CD30+ lymphomatoid reaction	Lymphoma Lymphomatoid papulosis
Dermatomyositis-like reaction	Lupus erythematosus
Drug reaction with eosinophils and systemic symptoms	Spongiotic dermatitis Pustular dermatitis Interface dermatitis Interstitial granulomatous dermatitis
Sarcoidal granulomatous dermatitis	Infection (including tuberculoid leprosy) Foreign body granuloma Sarcoidal variant of granuloma annulare Cutaneous Crohn’s disease Necrobiosis lipoidica Granuloma annulare
Interstitial granulomatous dermatitis	Interstitial granuloma annulare
Lichenoid dermatitis	Lichen planus Lichenoid keratosis Lichen nitidus Lichen Striatus Fixed drug reaction Discoid lupus erythematosus
Neutrophilic dermatosis of the dorsal hands	Infection Vasculitis Pyoderma gangrenosum Granuloma faciale Bechet disease
Panniculitis	Erythema nodosum Lupus panniculitis Other panniculitides Infection
Photosensitivity	Other spongiotic dermatitides
Prurigo nodularis	Verruca vulgaris Pseudocarcinomatous hyperplasia Keratoacanthoma
Psoriasis	Chronic spongiotic dermatitis Seborrheic dermatitis Pityriasis rubra pilaris Syphilis Lichen simplex chronicus
Pyoderma gangrenosum	Infection Vasculitis Sweet syndrome Granuloma faciale Bechet Disease
Sclerodermoid reaction	Morphea Sclerodermoid GVHD Chronic porphyria cutanea tarda Keloid Late-stage radiation dermatitis Lichen sclerosus Borrelia infection
Spongiotic dermatitis	Allergic contact dermatitis Atopic dermatitis Psoriasis Stasis dermatitis Id reaction Pityriasis rosea Tinea infection
Stevens-Johnson syndrome/toxic epidermal necrolysis-like reaction	Erythema multiforme GVHD Lupus erythematosus Dermatomyositis
Superficial perivascular dermatitis	Urticaria Arthropod bite reaction Drug reaction Scabies Urticarial bullous pemphigoid Allergic contact dermatitis Itchy red bump disease
Sweet syndrome	Infection Vasculitis Pyoderma gangrenosum Granuloma faciale Bechet disease
Xerosis	Ichthyosis “Invisible” dermatoses (macular amyloidosis, dermal melanocytosis, mastocytosis, anetoderma, vitiligo, tinea infection)

Figure 1. Pink firm nodules, round crusted plaques, erosions with violaceous rim at initial presentation (A–C) and 2 weeks after initial presentation (D). A) Right groin. B) Right thigh. C) Right medial ankle. D) Right medial ankle.

Goldkuhle M, Dimaki M, Gartlehner G, et al. Nivolumab for adults with Hodgkin’s lymphoma (a rapid review using the software RobotReviewer). Cochrane Database Syst Rev. 2018;7(7):CD012556.

 PubMedGoogle Scholar

Data availability statement

Data sharing not applicable – no new data generated